Trial Profile

An Open-label, Partially Randomized, 5-way Crossover Study in Healthy Volunteers to Assess the Relative Bioavailability of 100 and 150 mg Fostamatinib Tablets Compared With 50 mg Fostamatinib Tablets.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fostamatinib (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T-cell lymphoma
Focus Pharmacokinetics

27 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
27 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
16 Aug 2011 Actual initiation date (Aug 2011) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com